\"Novus ordo seclorum\": new applications af monoclonal antibodies in breast cancer

Apply

\"Novus ordo seclorum\": new applications af monoclonal antibodies in breast cancer

Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 10

Abstract

Trastuzumab (Herceptin) is a recombinant humanized monoclonal IgG1 antibody inhibiting selectively HER2 receptor in tumour cells, that has found a clinical application in breast cancer treatment. Until recently, this compound has been used exclusively in advanced breast cancer patients. During the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) preliminary results of three large randomized studies were presented in which trastuzumab in combination with chemotherapy was administered in the adjuvant setting in operable breast cancer patients with HER2 expression or amplification. Two of these studies (NSABP-31 and NCCTG-N9831) were performed by the American cooperative groups: the National Surgical Adjuvant Breast and the Bowel Project (NSABP) and the North Central Cancer Treatment Group (NCCTG), and the third one (HERA) was a global enterprise coordinated by the Breast Intergroup (BIG) in Brussels. The presented results demonstrated a surprisingly positive impact of trastuzumab: the relative risk of disease failure was halved and additionally, in the two American studies the risk of death was significantly reduced. The treatment was well tolerated and the only serious adverse side effect was an increased risk of cardiotoxicity. At the same session, results of the first study of the third phase were presented showing a significant increase of time to progression associated with the addition of antiangiogenic monoclonal antibody – bevacizumab to standard chemotherapy of advanced breast cancer. This article presents the result of these studies and discusses their potential implications on changing standards of care in breast cancer.

Authors and Affiliations

Renata Duchnowska, Cezary Szczylik

Keywords

Evaluation of efficiency of different radiotherapy methods for brain metastases in patients with lung cancer

Lung cancer is the first most malignant cancer in men and 1/3 of cases are morbid and mortal. Lung cancer in women is second after breast cancer. Brain metastases occur in 40% to 60% of all cases. Median survival in the...

Superficial hyperthermia combined with hypofractionated radiotherapy of malignant melanoma metastases to skin and lymph nodes

Aim: The evaluation of combined radiohyperthermia in the treatment of skin and lymph nodes malignant melanoma metastases. Material and method: Material comprises 10 skin and 11 lymph nodes melanoma metastases (1...

EP ID EP139063
DOI -
Views 75
Downloads 0